The Phase III trial, which enrolled 1,074 patients, pitted the combination of Rybrevant and Lazcluze against AstraZeneca’s Tagrisso (osimertinib), which is considered the SOC, as a first-line ...

AstraZeneca presented new data on TAGRISSO® (osimertinib) at the European Lung Cancer Congress (ELCC) 2025, reinforcing its role as a backbone therapy across treatment stages for epidermal growth ...

LAURA Phase III trial of TAGRISSO in unresectable ... together reinforce osimertinib as an effective, safe and convenient treatment for patients with EGFR-mutated lung cancer across stages ...

Tagrisso (osimertinib) has been found to be associated with positive outcomes, including improvements in overall survival, among patients with unresectable stage 3 EGFR-mutant non-small cell lung ...

Amid an 18 percent increase in cancer drug sales, J&J executives shared hopes that recent overall survival data for the drug combo will be practice changing.

Results from multiple clinical trials showed that Tagrisso demonstrated survival benefits in EGFR ... that can address progression in the advanced setting, together reinforce osimertinib as an ...

Osimertinib (Tagrisso, AstraZeneca), continues to provide an overall survival (OS) benefit after definitive chemoradiotherapy (CRT) in patients with unresectable stage III epidermal growth factor ...

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and MET overexpression (OverExp) and/or amplification (Amp) following progressive disease (PD) on osi Savolitinib plus TAGRISSO ...

demonstrate the role of AstraZeneca’s TAGRISSO® (osimertinib), as monotherapy and as the backbone for novel combinations, across stages and settings of epidermal growth factor receptor-mutated ...

The primary endpoint is PFS. The trial is ongoing and will continue to assess the secondary endpoint of OS. Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI with proven clinical ...

LAURA Phase III trial of TAGRISSO in unresectable ... data for combinations that can address progression in the advanced setting, together reinforce osimertinib as an effective, safe and convenient ...